Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label palovarotene study in fibrodysplasia ossificans progressiva
2016-002526-36Phase 2Completed
- Sponsor
- Clementia Pharmaceuticals Inc.
- Start
- Jul 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of palovarotene in fibrodysplasia ossificans progressiva (FOP) (2 cohorts), sponsored by Clementia Pharmaceuticals Inc. Primary endpoint: Primary efficacy endpoint. Started Jul 2016; status: completed.
02
Drugs
palovarotene
03
Conditions
fibrodysplasia ossificans progressiva (FOP)
Beyond the preview
Go deeper on 2016-002526-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002526-36.